Clinical trials: Lower Urinary Tract Disorder
Overactive Bladder Syndrome
A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder.
This study will assess the efficacy of a 12-week treatment with darifenacin in increasing warning time, the time from first sensation of urgency to voiding, in patients with OAB.
- Trial name
- NCT00171145
- Testing
- Darifenacin
- Where
- United States
- Volunteers
- 445 people
- Sponsor
- Novartis
Urinary Incontinence
A Long-Term Extension Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity
This study will evaluate the long-term safety and efficacy of onabotulinumtoxinA (botulinum toxin Type A; BOTOX®) for the treatment of urinary incontinence due to neurogenic detrusor overactivity in participants who successfully…
- Trial name
- NCT01852058
- Testing
- OnabotulinumtoxinA
- Where
- 30 sites in United States, Belgium and 6 more
- Volunteers
- 95 people
- Sponsor
- Allergan
Stress Urinary Incontinence
Pippa Pessary Study (Clinical Trial)
This is an open label, interventional, single arm, multi-clinic study where each adult female participant with stress urinary incontinence (SUI) serves as her own control (vaginal pessary use vs. no vaginal pessary).
- Trial name
- NCT05611970
- Testing
- Vaginal pessary
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- Liv Labs Inc.
Stress Urinary Incontinence
Post-Market Clinical Follow-Up onTVT EXACT® Continence System
The objective of this single arm, post market, clinical study is to evaluate the performance of Gynecare TVT EXACT® Continence System in women undergoing retropubic mid-urethral sling surgery for Stress Urinary Incontinence (SUI).
- Trial name
- NCT04829994
- Testing
- Intervention
- Where
- 8 sites in United States, Austria and 4 more
- Volunteers
- 198 people
- Sponsor
- Ethicon, Inc.
Urinary Bladder, Overactive
A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076
This was a 40-week study to investigate how safe and effective solifenacin solution was in treating children or adolescents with symptoms of overactive bladder (OAB), who completed study 905-CL-076 (NCT01565707).
- Trial name
- LEOPARD (NCT01655069)
- Testing
- Solifenacin succinate suspension
- Where
- 39 sites in United States, Belgium and 14 more
- Volunteers
- 148 people
- Sponsor
- Astellas Pharma Europe B.V.
Overactive Bladder
A Clinical Trial to Evaluate the Efficacy and Safety of DR-3001 in Women With Overactive Bladder
This is a multicenter study to evaluate the efficacy and safety of 2 different doses of DR-3001. For eligible subjects the duration of the study will be approximately 20 weeks; this will consist of a 4-week screening period, a…
- Trial name
- NCT00685113
- Testing
- DR-3001
- Where
- 84 sites in United States, Canada
- Volunteers
- 1,104 people, healthy volunteers welcome
- Sponsor
- Duramed Research
Overactive Bladder
Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)
This study will assess the efficacy of vibegron compared with placebo in men with overactive bladder (OAB) symptoms on pharmacological therapy for benign prostatic hyperplasia (BPH) as defined by micturition and urgency episodes.
- Trial name
- NCT03902080
- Testing
- Vibegron
- Where
- 140 sites in United States, Belgium and 6 more
- Volunteers
- 1,105 people
- Sponsor
- Urovant Sciences GmbH
Urinary Incontinence
Study for a Magnetic Endourethral Sphincter Against Stress Urinary Incontinence
A second no-random open interventional pilot study sponsored by Relief srl
- Trial name
- RELIEF-2 (NCT05449639)
- Testing
- Relief implantation
- Where
- 3 sites in Italy
- Volunteers
- 20 people
- Sponsor
- Relief srl
Overactive Bladder, Pharmacokinetics
A Clinical Study to Determine the Effect of YM178 on the Pharmacokinetics of Warfarin in Healthy Subjects
This study investigates whether YM178 has an effect on the pharmacokinetics of warfarin, to exclude any drug-drug interaction between YM178 and warfarin, and evaluates the safety and tolerability of warfarin alone and combined…
- Trial name
- NCT00856570
- Testing
- warfarin, YM178
- Where
- France
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Incontinence, Urinary and Urinary Bladder, Overactive, Overactive Bladder
Effects Of GW679769 On Bladder Nerve Function And Symptoms Of Overactive Bladder In Spinal Cord Injury Patients
This is a two-part study in which Part A will assess the effects of GW679769 after 1 dose on the function of the nerves that supply the bladder. The technique for measuring the nerves function is called Neurometry.
- Trial name
- NCT00332319
- Testing
- GW679769
- Where
- 3 sites in United States
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Urge Incontinence
Protect Chronic Tibial Nerve Stimulator (CTNS) System
30 patient Study. All patients implanted with StimGuard Protect System. Patient followed out to 90 days.
- Trial name
- NCT02781636
- Testing
- Device: StimGuard Protect System
- Where
- Belgium
- Volunteers
- 10 people
- Sponsor
- Uro Medical Corporation
Benign Prostatic Hyperplasia
Study of a α1A Adrenoceptor Selective Antagonist Silodosin to Treat Severe Benign Prostatic Hyperplasia(BPH)
This clinical study is designed to evaluate the efficacy and safety of silodosin in a 12 week treatment of patients with severe urinary disorders associated with benign prostatic hyperplasia (BPH).
- Trial name
- STRONG (NCT01259531)
- Testing
- Silodosin
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- JW Pharmaceutical
Prostate Cancer
Study to Evaluate the Presence of Lower Urinary Tract Symptoms (LUTS) in Prostate Cancer Patients Scheduled to Receive Luteinizing Hormone Releasing Hormone (LHRH) Analogues
The intention of this study is to investigate how many patients with prostate cancer, planned to be treated with LHRH analogues without history of surgery or radiotherapy, are suffering from LUTS.
- Trial name
- ANALUTS (NCT02542501)
- Where
- 32 sites in Portugal, Spain
- Volunteers
- 470 people
- Sponsor
- Ipsen
Urinary Incontinence , Stress
Monocentric Pilot Study for the Application of an Endourethral Device for the Treatment of Stress Urinary Incontinence
Stress urinary incontinence is defined as the involuntary loss of urine during exertion or physical activity (i.e., sports) or during sneezing or coughing.
- Trial name
- CIP-003 (NCT07327528)
- Testing
- UroRelief, a sterile, single-use, endourethral medical device suitable for both men and women, which is positioned at the bladder neck for the treatment of stress incontinence.
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Relief srl
Prostatism, Erectile Dysfunction
Study of Dr. Pyke's Supplement for Stream (S4S) in Men With Prostatism and ED
This is the first clinical trial of Dr. Pyke's Supplement for Stream (S4S), a proprietary combination of Panax ginseng extract, L-citrulline, beta-sitosterol and vitamin D3, to investigate its effects on prostatism and erections…
- Trial name
- S4S4BPH/ED (NCT03681392)
- Testing
- Dr. Pyke's Supplement for Stream (S4S)
- Sponsor
- Robert E. Pyke
Stress Urinary Incontinence
Altis® 522 Trial - Treatment of Female Stress Urinary Incontinence
The aim of this postmarket study is to compare the safety and effectiveness of the Altis Single Incision Sling (SIS) to an FDA cleared transobturator and/or retropubic sling through 36 months.
- Trial name
- NCT02348112
- Testing
- Altis Single Incision Sling, Transobturator or Retropubic Sling
- Where
- 27 sites in United States, Canada
- Volunteers
- 416 people
- Sponsor
- Coloplast A/S
Urinary Incontinence
Effectiveness and Safety of Bulkamid® as Bulking Agent for the Treatment of Female Urinary Incontinence
To assess effectiveness of Bulkamid® injection in females suffering from stress or mixed (stress and urge) urinary incontinence after 12 months follow up period
- Trial name
- NCT00333073
- Testing
- Bulkamid
- Where
- 10 sites in Denmark, Finland and 3 more
- Volunteers
- 125 people
- Sponsor
- Contura
Benign Prostatic Hyperplasia
Safety and Efficacy of Botulinum Toxin Type A to Treat Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
This study will evaluate the safety and efficacy of intraprostatic administration of botulinum toxin Type A (BOTOX®) compared with placebo to treat urinary tract symptoms due to benign prostatic hyperplasia.
- Trial name
- NCT01107392
- Testing
- botulinum toxin Type A, Normal saline
- Where
- 8 sites in United States, Canada and 6 more
- Volunteers
- 315 people
- Sponsor
- Allergan
Urinary Bladder Overactive, Overactive Bladder
A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)
A study to identify factors that are associated with improved effectiveness in pharmacologic therapy of Overactive Bladder, from the patient perspective primarily measured by OAB-Q-SF (Overactive Bladder Questionnaire Short Form)
- Conditions
- Urinary Bladder Overactive, Overactive Bladder, Urinary Bladder Diseases, Urologic Diseases
- Trial name
- PERSPECTIVE (NCT02386072)
- Testing
- mirabegron, antimuscarinic medication
- Where
- 92 sites in United States, Canada
- Volunteers
- 1,524 people
- Sponsor
- Astellas Scientific & Medical Affairs, Inc.
Overactive Bladder
Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR)
The purpose of this study is to compare the safety and efficacy of solifenacin with oxybutynin immediate-release (IR) for the treatment of overactive bladder (OAB).
- Trial name
- VECTOR (NCT00431041)
- Testing
- solifenacin, oxybutynin immediate release
- Where
- 12 sites in Canada
- Volunteers
- 132 people
- Sponsor
- Astellas Pharma Inc